<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04304066</url>
  </required_header>
  <id_info>
    <org_study_id>2019KT116/2019KT62</org_study_id>
    <nct_id>NCT04304066</nct_id>
  </id_info>
  <brief_title>Research for the Molecular Imaging of the PD-L1 Targeting Tracer</brief_title>
  <official_title>Research for the Molecular Imaging of the PD-L1 Targeting Tracer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Cancer Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To use the molecular probe PET radionuclide (Ga-68 or F-18) WL12 peptide to detect the&#xD;
      expression of PD-L1 in the primary and metastatic lesions in patients with solid tumor; to&#xD;
      detect the expression heterogeneity of PD-L1 in the lesion and inter-lesions; to observe the&#xD;
      change of PD-L1 expression in the course of treatment. To provide an approach for screening&#xD;
      patients with high expression of PD-L1, efficacy monitoring, drug resistance and early&#xD;
      warning of recurrence and metastasis to achieve the Individualized antitumor treatment of&#xD;
      targeted drugs.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In many clinical trials, Anti-PD-1/PD-L1 mAbs have achieved great success than expected in a&#xD;
      variety of refractory and recurrent tumor patients. The latest research shows that it is not&#xD;
      all cancer patients would respond to Anti-PD-1/PD-L1 mAbs. At present, immunohistochemistry&#xD;
      (IHC) is still a common method to screen patients that will benefit from this therapy by&#xD;
      detecting the expression level of PD-1 and PD-L1. However, the results of IHC were not very&#xD;
      exact because of limitations of IHC such as the heterogeneity of expression, the influence of&#xD;
      host cell PD-L1 expression and the changes in the course of the disease. Moreover, the tumor&#xD;
      tissue used in IHC must obtained through the invasive method. It is difficult to dynamically&#xD;
      monitor the expression level of PD-1 / PD-L1 during the treatment. Immuno-PET molecular&#xD;
      imaging By radiolabeling Anti-PD-1/PD-L1 mAbs with radionuclides can be used to noninvasive&#xD;
      assessment of biodistribution of monoclonal antibodies and provide a new strategy for patient&#xD;
      screening.&#xD;
&#xD;
      In this study, 18F-WL12 or 68Ga-WL12 PET / CT imaging will be performed in patients with&#xD;
      solid tumors to access the potential of 18F-WL12 or 68Ga-WL12PET / CT to screen patients who&#xD;
      can benefit from JS001 treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 17, 2020</start_date>
  <completion_date type="Anticipated">April 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SUV</measure>
    <time_frame>2 years</time_frame>
    <description>The uptake of the tracer in the primary and metastatic tumor lesions by measuring standardized uptake value（SUV）on PET/CT</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Solid Tumor</condition>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Imaging cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All study participants will be allocated to this arm (single-arm study).Study participants will undergo 18F-WL12 or 68Ga-WL12 PET/CT scans</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>18F-WL12 PET or 68Ga-WL12 PET</intervention_name>
    <description>WL12, labeled with PET radio-nuclide ( Ga-68 or F-18)will be used as a molecular imaging tracer for PET/CT scanning</description>
    <arm_group_label>Imaging cohort</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. Aged &gt;18 years old; ECoG 0 or 1;&#xD;
&#xD;
          -  2. Patients with solid tumors;&#xD;
&#xD;
          -  3. Has at least one measurable target lesion according to Response Evaluation Criteria&#xD;
             in Solid Tumors (RECIST V1.1);&#xD;
&#xD;
          -  4. life expectancy &gt;=12 weeks.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Significant hepatic or renal dysfunction;&#xD;
&#xD;
          -  2. Is pregnant or ready to pregnant;&#xD;
&#xD;
          -  3. Cannot keep their states for half an hour;&#xD;
&#xD;
          -  4. Refusal to join the clinical study;&#xD;
&#xD;
          -  5. Suffering from claustrophobia or other mental diseases;&#xD;
&#xD;
          -  6. Any other situation that researchers think it is not suitable to participate in the&#xD;
             experiment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hua Zhu</last_name>
    <phone>010-88196495</phone>
    <email>zhuhuabch@pku.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shunlian Zhou</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shunlian Zhou</last_name>
      <phone>010-88196391</phone>
      <email>zhoushunlian@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>March 9, 2020</study_first_submitted>
  <study_first_submitted_qc>March 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 11, 2020</study_first_posted>
  <last_update_submitted>September 5, 2020</last_update_submitted>
  <last_update_submitted_qc>September 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Cancer Hospital</investigator_affiliation>
    <investigator_full_name>Hua Zhu</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

